10 outubro 2016
Fresenius Medical Care, the world’s largest provider of dialysis products and services, is celebrating its 20th anniversary.
2 setembro 2016
Fresenius Medical Care, the world’s largest provider of dialysis products and services, today announced to acquire 85% of equity interest in Indian dialysis group Sandor Nephro Services from a group of investors. The parties involved agreed not to disclose financial terms of the transaction.
1 agosto 2016
“Following a solid start to the year, we have accelerated our growth in the second quarter”, said Rice Powell, Chief Executive Officer of Fresenius Medical Care. “Our strong earnings growth demonstrates our ability to further improve our cost base and the success of our Global Efficiency Program. I am extremely pleased with our excellent operational performance in the core dialysis services business.
1 agosto 2016
Stephan Sturm, CEO of Fresenius, said: “Once again, all four business segments contributed to strong organic growth. This confirms Fresenius’ sound strategic position as a healthcare Group. We have continued to grow even in regions where economies have slowed. This confirms the stability of our markets and businesses.
31 maio 2016
Fresenius Medical Care establishes regenerative medicine subsidiary, to continue successful work with University of Turin
Fresenius Medical Care, the world’s largest provider of dialysis products and services, has established a subsidiary focusing on regenerative medicine. Unicyte AG will pursue research into kidney and liver diseases, diabetes and cancer, and will work with additional partners when needed to advance these projects.
25 maio 2016
Fresenius Medical Care launches 6008 CAREsystem, a new hemodialysis therapy system enabling better care for chronic patients
Fresenius Medical Care, the world’s largest provider of dialysis products and services, has launched the 6008 CAREsystem for the treatment of patients with end-stage renal disease (ESRD). This new dialysis therapy system incorporates Fresenius Medical Care’s highest therapy standards while optimizing dialysis treatment and improving economic efficiency. Most importantly, it minimizes the number of risk-related handling steps and reduces complexity in therapy delivery.
12 maio 2016
Fresenius Medical Care expects continued, stong growth - Annual General Meeting approves consecutive dividend increase
Fresenius Medical Care, the world’s leading provider of dialysis products and services, expects significant sales and earnings growth in 2016. At the Annual General Meeting in Frankfurt today, CEO Rice Powell confirmed the full-year guidance announced in February. The company is targeting 7 to 10 percent revenue growth in constant currency, and an increase in net income of 15 to 20 percent.
11 março 2016
Fresenius Medical Care anounces proposals for election to the Supervisory Board by the Annual General Meeting on May 12, 2016
The Supervisory Board of Fresenius Medical Care AG & Co. KGaA has decided in its meeting on March 9, 2016, to propose to the Annual General Meeting on May 12, 2016 the following candidates for regular election to the Supervisory Board
18 fevereiro 2016
Fresenius Medical Care reaches agreement in principle to resolve the GranuFlo®/NaturaLyte® product liability litigation
Fresenius Medical Care AG & Co. KGaA (“the company” or “Fresenius Medical Care”), the world’s largest provider of dialysis products and services, today announced that Fresenius Medical Care North America (FMCNA) has reached an agreement in principle with a committee designated by the plaintiffs to resolve litigation in the United States involving GranuFlo®®/NaturaLyte.
10 dezembro 2015
Fresenius has put its new website online: www.fresenius.com. The relaunched website combines technology and design in a modern, user-friendly Internet format. The content has been updated and rearranged, with easy-to-use navigation. Powerful photographs on the homepage will guide visitors to interesting topics. The responsive design optimizes the display of all content on mobile devices and ensures quick loading times.
29 outubro 2015
Ulf Mark Schneider, CEO of Fresenius, said: “Our strong growth trend continued with doubledigit constant currency sales and earnings growth in the first nine months. All business segments contributed to the excellent financial results. Fresenius Kabi in particular stood out, benefiting from drug shortages and new product launches in the U.S. market. We raise our Group earnings guidance for 2015 and remain optimistic about the positive fundamentals in our markets.”
1 setembro 2015
Fresenius Medical Care releases new adsorder IgEnio® in Europe for treatment of severe allergic symptoms
Fresenius Medical Care has released a new single-use adsorber for the treatment of IgE (ImmunoglobulinE)-mediated diseases in the European market.
1 setembro 2015
Fresenius SE & Co KGaA will be included in the EURO STOXX 50 blue-chip index on September 21, 2015. The index update was announced by the Deutsche Börse subsidiary STOXX after the close of trading on Monday night. The EURO STOXX 50 index tracks the share price development of 50 large publicly traded companies, representing various economic sectors, from twelve Eurozone countries.
27 agosto 2015
Fresenius expects 2015 dividend increase of more than 20%, will reach mid-term Group net income target ahead of schedule
Fresenius expects a significant 2015 dividend increase, resulting from the forecasted 2015 net income growth applied to the company’s dividend policy. After raising guidance twice this year, Fresenius is forecasting 2015 net income growth of 18% to 21% in constant currency. In addition, the company expects a significant positive currency effect. 2015 dividend growth is therefore expected to clearly exceed 20%. This will mark the company’s 23rd consecutive year of dividend increases.
20 maio 2015
Fresenius SE & Co. KGaA Annual General Meeting: 2015 guidance confirmed, 22nd consecutive dividend increase approved
Fresenius expects to set new sales and earnings records in 2015. Ulf Mark Schneider, CEO of Fresenius, confirmed the company’s growth targets at the Annual General Meeting in Frankfurt today. The global healthcare group forecasts sales growth of 7 to 10 percent and an increase in net income of 13 to 16 percent this year, both in constant currency. After a strong first quarter, Fresenius had raised its earnings guidance in April.
18 maio 2015
Fresenius Medical Care confirms growth targets – Shareholders approve 18th consecutive dividend increase
Fresenius Medical Care, the world’s largest provider of dialysis products and services, is aiming to increase sales and earnings in the coming years. At today’s Annual General Meeting in Frankfurt, chief executive officer Rice Powell confirmed the company’s growth targets for 2015 and beyond. Revenue is expected to increase by 10 to 12% in constant currency and net income by up to 5%. In 2016, the company expects net income to grow by 15 to 20%, and revenue to increase by 9 to 12% in constant currency.
4 maio 2015
Fresenius Medical Care AG & Co. KGaA, the world’s largest provider of dialysis products and services, has launched multiFiltratePRO, a therapy system for continuous renal replacement therapy (CRRT), for the treatment of acute kidney failure in critically ill patients at intensive care units.
25 fevereiro 2015
Sales and net income reach all-time highs – 6% dividend increase proposed – Positive Group outlook for 2015
Ulf Mark Schneider, CEO of Fresenius, said: „2014 was a challenging but successful year for Fresenius. We made significant progress on the integration of the Rhön hospitals, strengthened the Care Coordination initiatives at Fresenius Medical Care, and set new sales and earnings records for the Group. Fresenius sees significant opportunities arising from the increasing demand for affordable, high-quality health care around the globe. We remain highly optimistic about the growth prospects in all our business segments for 2015 and beyond.”
19 janeiro 2015
Fresenius refinances its credit agreement - Standard & Poor's upgrades Fresenius' credit rating to investment grade
Fresenius has launched a refinancing of the revolving facilities and the term loan A tranches (aggregate volume approx. €3 bn) under its 2013 senior credit agreement. The maturity will be extended by 2 years to June 28, 2020. Given the improved credit profile and favorable bank market conditions, Fresenius’ proposal also includes reduced credit margins.
27 novembro 2014
Fresenius Medical Care successfully upsizes and extends the maturity of its credit agreement and also extends the maturity of its accounts receivable facility
Fresenius Medical Care AG & Co. KGaA (the “company” or “Fresenius Medical Care”; Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS), the world’s largest provider of dialysis products and services, has upsized its syndicated credit facility by 850 million U.S. dollar equivalent to a total amount of approximately 4.4 billion U.S. dollar equivalent, with pricing and other conditions more favorable to the company. The amended credit facility consists of revolving facilities and term loans, both U.S. dollar and euro denominated. The final maturity date was extended by two years to October 30, 2019. The facilities will be used to refinance existing debt, for working capital needs and general corporate purposes.
13 novembro 2014
Fresenius Medical Care AG & Co. KGaA (the “company” or “Fresenius Medical Care”; Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS) announced today that Sound Physicians Inc. (Sound) has entered into an agreement to acquire Cogent Healthcare (Cogent) with more than 650 providers, who offer hospitalist and intensivist services to more than 80 hospitals throughout the United States. Combined, the expanded Sound Physicians organization will now serve over 180 hospitals in 35 states with more than 2,250 providers including physicians and advanced care practitioners. Fresenius Medical Care is the majority shareholder in Sound.
23 outubro 2014
The Supervisory Board of Fresenius SE & Co. KGaA will propose that the next Annual General Meeting elect Mr. Michael Diekmann to the Supervisory Board. The Supervisory Board believes that his immense expertise and experience qualify Mr. Diekmann for the position of Deputy Chairman, which is now vacant. If elected to the Board, Mr. Diekmann has declared that he will seek this post.
23 outubro 2014
Fresenius Medical Care expands further in care coordination with the acquisition of National Cardiovascular Partners
Fresenius Medical Care AG & Co. KGaA (the “company” or “Fresenius Medical Care”; Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS), the world’s largest provider of dialysis products and services, today announced the acquisition of National Cardiovascular Partners (“NCP”). The parties involved agreed not to disclose the financial terms of the acquisition.
15 setembro 2014
Fresenius Medical Care introduces new sleep safe harmony cycler for a Peritoneal Dialysis therapy tailored to patients' needs
Fresenius Medical Care, the world’s largest provider of dialysis products and services, has launched a new cycler that delivers a Peritoneal Dialysis (PD) therapy tailored to individual patients’ needs. sleep•safe harmony was presented to leading specialists from around the world at two scientific congresses in Berlin and Madrid on September 6 and 7. The device is available from now on in selected countries including Germany, Spain, Great Britain and France.
27 junho 2014
Company executes on the strategy disclosed earlier this year to invest in care coordination around dialysis. The investment clearly advances the commitment to address the full spectrum of care for chronically ill patients.
16 maio 2014
Fresenius SE & Co. KGaA Annual General Meeting:Stock split and 21st consecutive dividend increase approved
A large majority of 99.48% Fresenius SE & Co. KGaA shareholders approved a three-for-one stock split at the company’s Annual General Meeting in Frankfurt today. Every shareholder will receive two additional shares for each share held.
15 maio 2014
Fresenius Medical Care confirms long-term growth targets - Shareholders approve 17th consecutive dividend increase
Fresenius Medical Care expects continued strong growth in the coming years. At today’s Annual General Meeting in Frankfurt, Rice Powell, chief executive officer, confirmed the long-term targets announced in April.
15 abril 2014
Fresenius Medical Care and Joslin Diabetes Center Partner to Improve Health of Patients with Diabetic Kidney Disease
Fresenius Medical Care AG & Co. KGaA (the “company” or “Fresenius Medical Care”; Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS), the world’s largest provider of dialysis products and services, and Joslin Diabetes Center, Inc., the world's preeminent diabetes research, clinical care and education organization, announced an agreement today to jointly develop renal care programs in select Joslin Affiliated Centers for patients with diabetic kidney disease (DKD).
12 março 2014
Fresenius Medical Care, the world's largest provider of dialysis products and services, today announced two changes in the Management Board.
25 fevereiro 2014
Targets achieved for fiscal year 2013 - Further expansion of global franchise and new record level of revenue - Increased dividend to be proposed at the Annual General Meeting.
5 novembro 2013
Fresenius Medical Care AG & Co. KGaA (the “company” or “Fresenius Medical Care”; Frankfurt Stock Exchange: FME/New York Stock Exchange: FMS), the world’s largest provider of dialysis products and services, today announced its results for the third quarter and first nine months of 2013.
2 setembro 2013
Dr. Gerd Krick, Chairman of the Supervisory Board of Fresenius, will celebrate his 75th birthday on October 8. Before he moved to the Supervisory Board in 2003, Dr. Krick spent almost three decades in top management positions at Fresenius, including 11 years as Chief Executive Officer.
30 julho 2013
Fresenius Medical Care AG & Co today announced its results for the second quarter and first half of 2013.